A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Trial Profile

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Prednisolone; Vincristine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Results assessing approach and feasibility of patient reported outcome presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Nov 2016 According to Seattle Genetics media release, data will be presented at the 58th American Society of Hematology (ASH) Annual Meeting Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top